March 12, 2024
1 min watch
Save
VIDEO: New treatments add tools to the armamentarium for retinal vein occlusion
In this expert perspective from Hawaiian Eye 2024, Kent W. Small, MD, discusses important developments in the treatment of retinal vein occlusion, or RVO.
“Faricimab is now approved for RVOs and macular edema secondary to RVOs, so that’s been helpful,” Small said of the most significant development in RVO in 2023.
Looking forward, Small, of the Macula and Retina Institute in Glendale and Los Angeles, anticipates the approval of Eylea HD (aflibercept 8 mg, Regeneron) for RVO, which would add another tool to the armamentarium.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Small reports no relevant financial disclosures.
Read more from Expert Perspectives in RVO
View allRead more about